Welcome to the e-CCO Library!

P601: Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study
Year: 2022
Source: ECCO'22
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);di Giuseppe, R.(2);Deppe, H.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atrya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann, P.(3);Schreiber, S.(13);
Created: Friday, 11 February 2022, 3:56 PM
P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Panaccione1*, R. Atreya2, M. Ferrante3, M.C. Dubinsky4, B.E. Sands4, M.T. Abreu5, F. Cataldi6, J.V. Enejosa6, Q. Zhou6, B. Huang6, A.P. Lacerda6, A.L. Pangan6

Created: Thursday, 21 February 2019, 9:14 AM
P602 Changes in emotional health and work-related outcomes in patients with moderate to severe ulcerative colitis 1 year after diagnosis: Results from the MOSAIK cohort in Korea
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. PARK1, J.H. Cheon1, Y.S. Park2, K.C. Huh3, J.E. Shin4, J.M. Cha5, Y.S. Kim6, C.S. Eun7, S.M. Yoon8, Y.S. Park9, B.D. Ye10, B. Seo11, Y. Kim11, MOSAIK

Created: Thursday, 30 January 2020, 10:12 AM
P602: Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Magro, F.(1)*;Peyrin-Biroulet, L.(2,3);Sands, B.E.(4);Danese, S.(5);Jairath, V.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Ferreira Branquinho, D.(10);Modesto, I.(11);Feagan, B.G.(12);
Created: Friday, 14 July 2023, 11:05 AM
P602: CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Svolos*1, R. Hansen2, U. Z. Ijaz3, L. Gervais2, H. Duncan2, R. Tayler2, A. Barclay2, D. Flynn2, V. Garrick2, L. Curtis2, E. Buchanan2, T. Cardigan2, D. R. Gaya4, S. Milling5, R. K. Russell2, K. Gerasimidis1

Created: Friday, 22 February 2019, 9:41 AM
P602: Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centre
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tighe D.*1,2, Breslin N.1, Ryan B.1, McNamara D.3

Created: Wednesday, 20 February 2019, 10:36 AM
P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

Created: Thursday, 21 February 2019, 9:14 AM
P602: Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.
Year: 2022
Source: ECCO'22
Authors: Blondeaux, A.(1);Speca, S.(2);Valibouze, C.(3);Lambin, T.(1);Dubuquoy, C.(2);Titecat, M.(4);Genoscreen, L.(5);Neut, C.(6);Genin, M.(7);Zerbib, P.(3);Foligne, B.(6);Desreumaux, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P602: Vedolizumab subcutaneous influencing disease course in Constant-care app solution
Year: 2021
Source: ECCO'21 Virtual
Authors: Nørgaard, J.(1);Malte, R.(1);Charlotte, P.L.(1);Mette, B.(1);Eva, F.(1);Petra, W.(1);Dorit, A.(1);Lotte, S.(1);Johan, B.(1);Pia, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, P. Dolin21

Created: Thursday, 30 January 2020, 10:12 AM
P603: Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

García V.*1, Calvo M.2, Martín Arranz M.D.3, Rivero M.4, Domènech E.5, Barreiro-de Acosta M.6, García Planella E.7, Gutiérrez A.8, Romero C.9, Cea-Calvo L.9, Juliá B.9

Created: Wednesday, 20 February 2019, 10:36 AM
P603: INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas
Year: 2022
Source: ECCO'22
Authors: Zmora, O.(1);Baumgart, D.C.(2);Faubion, W.(3);Ferrante, M.(4);Gecse, K.(5);Genestin, E.(6);Geransar, P.(6);Hantsbarger, G.(7);Karki, C.(8);Tozer, P.(9);Panés, J.(10);
Created: Friday, 11 February 2022, 3:56 PM
P603: Paediatric onset inflammatory bowel disease is not associated with more disability compared with adult onset disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Picardo*1, R. Panaccione1, G. Kaplan1,2, C. Seow1,2, J. deBruyn3, Y. Leung1,4

Created: Friday, 22 February 2019, 9:41 AM
P603: Patient characteristics and adverse effects in biologic treatment of Crohn’s Disease and Ulcerative Colitis: A nationwide Danish cohort study years 2015-2018.
Year: 2021
Source: ECCO'21 Virtual
Authors: Bjørn Jensen, C.(1);Jarlov Jensen, K.(1);Wennerström, C.(2);Sommer, K.J.(3);Burisch, J.(4);Petersen, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P603: Real-world Scottish experience of anti-TNF therapy in paediatric Crohn's disease 2016-2020 against the ECCO-ESPGHAN recommendations
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wands , D.(1)*;Scott , G.(2);Wilson , D.C.(1);Hansen , R.(2);Chalmers , I.(3);
Created: Friday, 14 July 2023, 11:05 AM
P603: Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Hanžel1*, N. Sever1, I. Ferkolj1, B. Štabuc1, N. Smrekar1, M. Koželj1, G. Novak1, A. Gils2, D. Drobne1

Created: Thursday, 21 February 2019, 9:14 AM
P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. REES1, A. Packham1, C. Blake1, E. Hills1, G. Scutt2, A. St Clair-Jones1

Created: Thursday, 30 January 2020, 10:12 AM
P604: Biologics with or without a combination with 5-ASA in ulcerative colitis: frequency of usage and effect on the course of disease in the Swiss IBD-Cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Roth*1, P. Schreiner1, J-B. Rossel2, B. Misselwitz3, M. Scharl1, G. Rogler1, L. Biedermann1

Created: Friday, 22 February 2019, 9:41 AM
P604: Evaluation of management heterogeneity and complications of Crohn’s disease in Catalonia. A population quality care study
Year: 2021
Source: ECCO'21 Virtual
Authors: Brunet, E.(1);Melcarne, L.(1);Llovet, L.(1);Vela, E.(2);Cleries, M.(2);Pontes, C.(3,4);Garcia-Iglesias, P.(1,5);Albert, V.(1,5,6);Calvet, X.(1,5,6);
Created: Wednesday, 2 June 2021, 4:12 PM
P604: Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study.
Year: 2022
Source: ECCO'22
Authors: Bozon, A.(1);Serrero, M.(2);Caillo, L.(3);Gilletta, C.(4);Benezech, A.(5);Nancey, S.(6);Combes, R.(7);Danan, G.(8);Akouete, S.(1);Pages, L.(1);Bourgaux, J.F.(3);Boivineau, L.(1);Meszaros, M.(1);Altwegg, R.(1);
Created: Friday, 11 February 2022, 3:56 PM